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Background: The vascular disrupting agent ombrabulin shows synergy with docetaxel in vivo. Recommended phase II doses
were determined in a dose escalation study in advanced solid tumours.
Methods: Ombrabulin (30-min infusion, day 1) followed by docetaxel (1-h infusion, day 2) every 3 weeks was explored.
Ombrabulin was escalated from 11.5 to 42mgm 2 with 75mgm 2 docetaxel, then from 30 to 35mgm 2 with 100mgm 2
docetaxel. Recommended phase II dose cohorts were expanded.
Results: Fifty-eight patients were treated. Recommended phase II doses were 35mgm 2 ombrabulin with 75mgm 2 docetaxel
(35/75mgm 2; 13 patients) and 30mgm 2 ombrabulin with 100mgm 2 docetaxel (30/100mgm 2; 16 patients). Dose-limiting
toxicities were grade 3 fatigue (two patients; 42/75, 35/100), grade 3 neutropaenic infection (25/75), grade 3 headache (42/75),
grade 4 febrile neutropaenia (30/100), and grade 3 thrombosis (35/100). Toxicities were consistent with each agent; mild nausea/
vomiting, asthaenia/fatigue, alopecia, and anaemia were common, as were neutropaenia and leukopaenia. Diarrhoea,
nail disorders and neurological symptoms were frequent at 100mgm 2 docetaxel. Pharmacokinetic analyses did not show
any relevant drug interactions. Ten patients had partial responses (seven at 30mgm 2 ombrabulin), eight lasting 43 months.
Conclusions: Sequential administration of ombrabulin with 75 or 100mgm 2 docetaxel every 3 weeks is feasible.
Vascular disrupting agents (VDAs) exploit the often fragile
structure of existing tumoural blood vessels via a variety of
different mechanisms, ultimately resulting in vascular shutdown
and tumour necrosis. Some VDAs cause increased vascular
permeability of the arteriolar system by targeting rapidly
proliferating and immature endothelial cells, resulting in their
detachment from vessel walls (Hori and Saito, 2003). Ombrabulin
(AVE8062, AC-7700), a microtubule-destabilising agent, is one
such molecule currently under clinical investigation. This synthetic
derivative of the water-soluble VDA combretastatin A4 phosphate
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(CA4P), binds at or near the colchicine site on the b-subunit of
tubulin, leading to microtubule depolymerisation and cytoskeleton
disorganisation (Kanthou and Tozer, 2002).
Increased anti-tumour activity is anticipated when VDAs are
combined with other treatment modalities such as cytotoxic
chemotherapies, anti-angiogenic agents, external-beam radiotherapy,
and radioimmunotherapy (McKeage and Baguley, 2010). Encoura-
ging results, have been observed, such as the intriguing example of
the anti-VEGF antibody bevacizumab combined with CA4P
(Nathan et al, 2012) or ombrabulin (Del Conte et al, 2012).
Preclinical evaluation of ombrabulin with a range of chemo-
therapeutic agents revealed several promising combination
chemotherapy candidates. Docetaxel binds to tubulin (at a different
site to that of ombrabulin) and results in microtubule stabilisation
causing cell cycle arrest. Combining docetaxel with ombrabulin
yielded additive and sometimes synergistic activity in a range of
tumour cell lines at ombrabulin doses below the highest non-toxic
dose, as was demonstrated by fractional cell kill values and anti-
proliferative activity on endothelial cells when ombrabulin
administration preceded that of docetaxel by 24 h (Lejeune et al,
2005; Kim et al, 2007). This combination resulted in significant
survival improvements in multiple murine tumour models,
including breast and ovarian cancers, and was well tolerated.
Docetaxel is widely used to treat advanced and metastatic solid
tumours, in particular breast, hormone-refractory prostate, non-
small cell lung, head and neck, gastric, and ovarian cancers, either
as monotherapy or in combination with other agents.
In a phase I ombrabulin single-agent study, abdominal pain,
tumour pain, and hypertension were dose-limiting and 50mgm 2
was established as the recommended dose (Sessa et al, 2013).
The current two-step phase I study was designed to determine
the recommended phase II ombrabulin dose (RP2D) for use in
combination with two standard docetaxel doses (75 and
100mgm 2). Pharmacokinetic analyses were conducted to assess
potential interactions between ombrabulin and docetaxel and anti-
tumour activity was assessed.
PATIENTS AND METHODS
Patient selection. To be eligible, patients had to be aged 18–75
years and have a histologically or cytologically confirmed
metastatic or locally advanced tumour for which docetaxel
treatment was recommended. Eastern Cooperative Oncology
Group (ECOG) performance status 0 or 1, adequate haematolo-
gical, renal, and hepatic function, and appropriate washout since
prior therapy were required. In France, women with locally
advanced or metastatic breast cancer without prior adjuvant
chemotherapy were excluded. Patients with grade 2 or higher
peripheral neuropathy or chemotherapy-related grade 3 or higher
ototoxicity according to the National Cancer Institute Common
Toxicity Criteria for Adverse Events (NCI-CTCAE, version
3.0) were excluded, as were patients having received prior intensive
chemotherapy with autologous stem cell rescue or a high
cumulative anthracycline dose (doxorubicin 4400mgm 2 or
epirubicin4750mgm 2), patients with severe hypersensitivity to
taxanes or polysorbate 80, a history of cardiac conditions,
left ventricular ejection fraction (LVEF) o50%, untreated
hypertension (systolic blood pressure (BP) 4140mmHg or
diastolic BP 490mmHg), patients receiving antihypertensive
medication (other than angiotensin converting enzyme inhibitors,
receptor antagonists, or diuretics), with hypertension-related organ
damage, Q-wave infarction or ST segment changes X1mm
(12-lead electrocardiogram (ECG)), or ventricular tachycardia
(Holter ECG). The study was approved by the ethics committees of
the two participating centres (Tarnier-Cochin Hospital, France,
and Erasmus MC Cancer Institute, The Netherlands) and was
conducted in accordance with the Declaration of Helsinki. All
patients gave written informed consent prior to enrolment. The
study is registered at ClinicalTrials.gov (NCT01907685).
Study design and treatment. This phase I dose escalation study
was performed between June 2006 and February 2011. Ombrabulin
(Sanofi, Vitry-sur-Seine, France) was administered as a 30-min
intravenous infusion on day 1, followed on day 2 by docetaxel (1-h
infusion, 24 h after the end of the ombrabulin infusion), every 3
weeks. Two docetaxel doses were evaluated. Initially 75mgm 2
docetaxel was investigated combined with ombrabulin at the
starting dose of 11.5mgm 2. This ombrabulin dose was selected
based on preclinical data suggesting that a minimal dose of
6mgm 2 was required for synergy with docetaxel, and from phase
I single-agent weekly and intermittent regimens showing that
11.5mg was safe. Once the RP2D with 75mgm 2 docetaxel was
established, 100mgm 2 docetaxel was investigated with ombra-
bulin at a starting dose of 30mgm 2. Medications metabolised by
CYP2C19 were omitted for 12 h prior to and after the ombrabulin
infusion. LHRH agonists administered to prostate cancer patients
were maintained. Growth factor treatment for therapeutic or
prophylactic intent was permitted throughout the study. Anti-
hypertensive prophylaxis was not administered.
A traditional 3þ 3 design was used with initially three patients
per dose level and three additional patients if dose-limiting toxicity
(DLT) occurred. Occurrence of DLT during the first cycle was
used to determine the RP2Ds. For each docetaxel dose, ombrabulin
dose escalation was stopped when two or more patients had DLT
during the first cycle, and the dose level immediately below was
considered the RP2Ds and expanded with 10 additional patients.
Dose-limiting toxicity was defined as grade 4 thrombocytopae-
nia, grade 4 neutropaenia lasting 45 days, grade 4 febrile
neutropaenia, grade 3 or 4 neutropaenic infection, any grade 3–4
non-haematological toxicity (other than nausea, vomiting, and
hypersensitivity without adequate treatment), or any of the
following cardiovascular events: documented angina pectoris,
arterial thromboembolism, grade 3–4 vascular events (except
tumour haemorrhage or necrosis), acute impairment of a target
organ (brain, heart, kidney), troponin I or creatine kinase (CK)-
MB increase above myocardial necrosis limits, systolic BP X180
mmHg and/or diastolic BP X120mmHg or grade X2 hypoten-
sion and/or systolic BP o90mmHg (in at least two successive
measurements at 30-min intervals), ST segment elevation or
depression X1mm in at least two contiguous leads or Q-wave
infarction on a 12-lead ECG, severe ventricular arrhythmia or ST
segment elevation or depression X2mm lasting X1min on a
Holter ECG, or grade 2 or higher LVEF, and any other toxicity
deemed dose-limiting, regardless of grade. Patients receiving at
least one combined ombrabulin-docetaxel administration with
clinical and laboratory examinations during the first cycle were
evaluable for DLT.
Adequate laboratory values (ANC X1.5 109/l, platelets
X100 109/l, ALT/AST/APpgrade 1, total bilirubin within
normal limits, total creatinine o1.5mg dl 1) and recovery from
any grade 3–4 toxicity to grade 1 or baseline levels were required at
the start of each cycle. A 1-week treatment delay was permitted for
related toxicity. Ombrabulin treatment was stopped if a cardio-
vascular DLT occurred or the patient did not recover from toxicity
following a 1-week delay. Ombrabulin dose reduction could be
implemented following DLT or grade 2 peripheral neuropathy with
recovery within 1 month or a repeat delay from the same toxicity.
Safety and tumour evaluations. Physical and neurological
examinations were performed weekly. Haematology was evaluated
weekly and biochemistry weekly for the first cycle and every cycle
thereafter. The following exams were performed within 4 weeks
prior to the first treatment administration, before each ombrabulin
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infusion, and as follows: a cardiovascular exam (6–12 and 24 h
post-ombrabulin), a 12-lead ECG (at 6–12 h post-ombrabulin), a
24-h Holter ECG, and CK-MB and troponin I (6–12 and 24 h post-
infusion). An echocardiography, an ocular funduscopy (in
hypertensive patients) and a brain MRI were performed within 4
weeks prior to treatment start. Chest X-rays were performed prior
to treatment then every 3 months. Adverse events (AEs) were
evaluated according to the NCI-CTCAE version 3.0. A central
review of cardiovascular toxicity was performed by an assigned
cardiologist. Tumour evaluation was performed every 6 weeks and
response was determined according to Response Evaluation
Criteria in Solid Tumours (RECIST) version 1.0 (Therasse et al,
2000). Objective responses had to be confirmed a minimum of 4
weeks after the initial criteria were met and stable disease (SD) had
to be derived from an evaluation a minimum of 5 weeks after the
first dose. Duration of objective response was from first
documented response until disease progression and duration of
SD was from first study drug administration until disease
progression.
Pharmacokinetics. The pharmacokinetics of ombrabulin and its
active metabolite RPR258063 were assessed in all patients using
2-ml blood samples collected in heparinised tubes on day 1 of cycle
1, pre-infusion, immediately prior to the end of the 30-min
infusion, and at 5, 10, 25, 45, and 60min then 2, 4, 6, 8–10, and
24 h post-infusion. Blood samples were collected for docetaxel
analysis in heparinised tubes pre-infusion (i.e., day 2 of cycle 1),
15min before the end of infusion, 15 and 45min, 2 and 5 h after
the end of the infusion. Samples were assayed with a validated
LC/MS/MS method using a limit of quantification of 2.0 ngml 1
for ombrabulin and RPR258063 and 1.0 ngml 1 for docetaxel.
Non-compartmental analyses for ombrabulin and RPR258063
including Cmax, Tmax, AUCt, t1/2Z, CL, and Vss were performed
using WinNonlin software, version 5.2.1 (Pharsight Inc., St Louis,
MO, USA). For docetaxel, CL and AUC were determined by
Bayesian estimation using NONMEM software, version V
(Globomax, Hanover, MD, USA). A three-compartment structural
model with first-order elimination was used as prior information
(estimates were CL 36.8 l h 1, Vd central compartment 7.83 L,
Vss 122 L, t1/2Z 10.0 h) (Bruno et al, 1996).
RESULTS
In total, 58 patients were treated, 39 with 75mgm 2 docetaxel and
19 with 100mgm 2 docetaxel. Patient and disease characteristics
are summarised in Table 1. The most common tumours were
breast (36%) and oesophageal (24%).
Dose-limiting toxicity. Dose-limiting toxicity was evaluated in
the first cycle, with 29 patients assessed at 75mgm 2 docetaxel
and 9 patients at 100mgm 2 docetaxel. Ombrabulin was escalated
from 11.5 to 42mgm 2 with 75mgm 2 docetaxel (Table 2). One
episode of DLT was seen in a patient at 25mgm 2 ombrabulin
consisting of grade 3 neutropaenic infection despite receiving
prophylactic G-CSF. At 42mgm 2 ombrabulin, DLTs were
reported in two patients, one with grade 3 headache (4 days
postombrabulin) and one with grade 3 fatigue. The RP2D
for 75mgm 2 docetaxel was set at 35mgm 2 ombrabulin
(35/75mgm 2) and an additional 10 patients were treated at this
dose level.
In the second step, 100mgm 2 docetaxel was evaluated with 30
and 35mgm 2 ombrabulin. One patient with 30mgm 2
ombrabulin had grade 4 febrile neutropaenia 1 week after the
docetaxel infusion, despite receiving prophylactic G-CSF. At
35mgm 2 ombrabulin, DLTs were reported in two patients, one
with grade 3 fatigue (2 days post-docetaxel) and one with grade 3
deep vein thrombosis (2 weeks postdocetaxel). The RP2D was set
at 30mgm 2 ombrabulin with 100mgm 2 docetaxel (30/
100mgm 2) and an additional 10 patients were enrolled at this
dose level.
Haematological toxicity. Grade 1–2 haematological toxicity was
common (Table 3) however anaemia was prevalent prior to
treatment (28% of patients). Grade 3–4 neutropaenia and
leukopaenia were reported at all dose levels, including 36% and
21% of patients treated with 75mgm 2 docetaxel, respectively,
and 58% and 53% of patients, respectively, at 100mgm 2.
No grade 3–4 thrombocytopaenia was reported. Prophylactic use
of G-CSF was permitted. During the first cycle, prophylactic
G-CSF was administered in 30 patients treated with 75mgm 2
docetaxel (77%) and 18 patients (95%) at 100mgm 2 docetaxel.
Overall G-CSF was administered in 32 (82%) and 19 (100%)
patients, respectively.
Non-haematological toxicity. Related non-haematological AEs
were mainly grade 1–2 (Table 4). At 75mgm 2 docetaxel, the
most common AEs were asthaenia/fatigue (69%), nausea (64%),
alopecia (56%), and vomiting (31%). Incidences were similar at
100mgm 2 docetaxel with the exception of asthaenia/fatigue
which was more frequent (95%). Additional toxicities at
100mgm 2 docetaxel included diarrhoea (68%), peripheral
sensory neuropathy/peripheral neuropathy (58%), nail disorders
(58%), dysgeusia/ageusia (58%), and peripheral oedema (42%).
Other cutaneous reactions were reported in 10% to 15% of patients
including hand/foot syndrome, erythema, and pruritus. Grade 1–2
hepatic enzyme elevations were common at all dose levels, however
baseline elevations in ALT and alkaline phosphatase were present
in 31% and 36% of patients, respectively.
Grade 3–4 non-haematological toxicities were reported in only
one patient each with the exception of alkaline phosphatase
elevations (four patients), fatigue (three patients), thrombosis, and
AST/ALT elevations (two patients each). One patient (15.5/
75mgm 2) had unrelated acute renal failure with grade 4
Table 1. Patient and disease characteristics
N patients treated 58
Female, N (%) 35 (60%)
Age in years, median (range) 53 (28–71)
Caucasian, N (%) 54 (93%)
ECOG performance status, N (%)
0/1 28 (48%)/30 (52%)
Primary tumour site, N (%)
Breast 21 (36%)
Oesophagus 14 (24%)
Muscle/soft tissue 5 (9%)
Pancreas 5 (9%)
Prostate 3 (5%)
Othera 10 (17%)
Metastatic disease, N (%) 52 (90%)
Prior therapy, N (%)
Chemotherapyb 49 (84%)
Surgery 39 (67%)
Radiotherapy 31 (53%)
Hormone 19 (33%)
Biologics 6 (10%)
Abbreviation: ECOG¼Eastern Cooperative Oncology Group.
aHead and neck (2), ovary (2), bladder, liver, skin (1 each), unknown (3).
bIncludes 33 patients (57%) with prior taxane therapy.
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creatinine elevation and hypernatraemia which recovered with
treatment. Related grade 4 sepsis occurred in one patient (20/
75mgm 2) which did not resolve despite treatment discontinua-
tion, developing to febrile neutropaenia and grade 3 respiratory
failure resulting in death. Two other patients (35/75mgm 2)
discontinued due to related events (grade 3 thrombosis and grade 2
gastrointestinal fistula). Ombrabulin dose reductions were reported
in four patients (at the two highest ombrabulin levels) following
grade 3 ALT, headache, or thrombosis. Docetaxel dose reductions
were implemented in 18 patients (31%), most at 30/100mgm 2
(9 of 16 patients), and were generally due to mild to moderate
oedema, fatigue/asthaenia, or skin/nail disorders. Of the 348 cycles
administered, 8 were delayed and 10 were temporarily interrupted
due to ombrabulin toxicity, whereas 27 docetaxel cycles were
interrupted due to toxicity.
Related cardiovascular events were reported in nine patients
(16%), mostly at 30mgm 2 ombrabulin or higher. Tachycardia
(atrial, sinus, or supraventricular) was reported in five patients,
palpitations in three patients, and AV block and sinus arrhythmia
in one patient each. Vascular events occurred in 22 patients (38%)
including phlebitis in five patients at a range of dose levels,
thrombosis in two and hypotension, flushing and haematoma in
one patient each. All related cardiovascular events were grade 1–2
with the exception of thrombosis (two grade 3 episodes). One
patient had a minimal LVEF decrease (47% compared with the
lower limit of 50%) and CK-MB elevations were noted in two
patients without concomitant cardiovascular events. A single case
Table 2. Treatment exposure and DLT
Dose level (mgm2) Median N cycles (range)
Docetaxel Ombrabulin N Patients Ombrabulin Docetaxel Cycle 1 DLT (N patients)
75 11.5 3 2 (1–3) 2 (1–3)
15.5 5 2 (2–14) 2 (2–12)
20 3 4 (4–4) 4 (4–4)
25 6 6.5 (2–12) 6.5 (2–10) G3 neutropaenic infection (1)a
30 3 8 (4–13) 6 (4–8)
35 3þ 10b 4 (1–22) 4 (1–22)
42 6 4 (1–8) 4 (1–8) G3 headache (1)
G3 fatigue (1)
100 30 6þ 10b 9.5 (2–16) 8 (2–15) G4 febrile neutropaenia (1)a
35 3 2 (2–4) 2 (2–4) G3 fatigue (1)
G3 thrombosis (1)
Abbreviation: DLT¼dose-limiting toxicity.
aBoth patients with neutropaenia received prophylactic G-CSF during cycle 1 and prior to the episode.
bTen additional patients were treated at the RP2D after dose escalation was completed.
Table 3. Haematological toxicity (NCI-CTCAE)
N patients (%)
11.5–42mgm2
ombrabulin/
75mgm2
docetaxel (N¼39)
30–35mgm2
ombrabulin/
100mgm2
docetaxel (N¼19)
All grades G3–4 All grades G3–4
Leukopaenia 22 (56%) 8 (21%) 15 (79%) 10 (53%)
Neutropaeniaa 18 (46%) 14 (36%) 13 (68%) 11 (58%)
Lymphopaenia 30 (77%) 8 (21%) 15 (79%) 7 (37%)
Anaemia 39 (100%) 1 (3%) 18 (95%) –
Thrombocytopaenia 14 (36%) – 9 (47%) –
Abbreviation: NCI-CTCAE¼National Cancer Institute Common Toxicity Criteria for Adverse
Events.
aNote that prophylactic G-CSF was administered at least once to 32 patients treated at
75mgm 2 docetaxel and all 19 patients treated at 100mgm 2 docetaxel.
Table 4. Non-haematological drug-related AEs, in 420% patients or
grade 3–4 (NCI-CTCAE)
N patients (%)
11.5–42mgm2
ombrabulin/
75mgm2
docetaxel (N¼39)
30–35mgm2
ombrabulin/
100mgm2
docetaxel (N¼19)
All grades G3–4 All grades G3–4
Nausea 25 (64%) – 11 (58%) –
Alopecia 22 (56%) – 13 (68%) –
Fatigue 15 (38%) 2 (5%) 8 (42%) 1 (5%)
Asthaenia 12 (31%) – 10 (53%) –
Vomiting 12 (31%) – 7 (37%) –
Decreased appetite 10 (26%) 1 (3%) 7 (37%) –
Diarrhoea 9 (23%) – 13 (68%) –
Dysgeusia 9 (23%) – 4 (21%) –
Peripheral sensory
neuropathya
3 (8%) – 9 (47%) –
Myalgia 6 (15%) – 7 (37%) –
Stomatitis 5 (13%) – 5 (26%) –
Oedema (peripheral) 4 (10%) – 8 (42%) –
Headache 3 (8%) 1 (3%) 4 (21%) –
Nail disorder 3 (8%) – 11 (58%) –
Ageusia 3 (8%) – 9 (47%) –
Increased lacrimation 2 (5%) – 7 (37%) –
Arthralgia 1 (3%) – 4 (21%) 1 (5%)
Thrombosis 1 (3%) 1 (3%) 1 (5%) 1 (5%)
Febrile neutropaenia – – 1 (5%) 1 (5%)
Hand/foot syndrome 2 (5%) – 3 (16%) 1 (5%)
Neutropaenic infection 2 (5%) 1 (3%) 1 (5%) –
Oesophageal fistula 1 (3%) 1 (3%) – –
Nail toxicity 2 (5%) 1 (3%) – –
Sepsis 1 (3%) 1 (3%) – –
Respiratory failure 1 (3%) 1 (3%) – –
Abbreviations: AE¼ adverse event; NCI-CTCAE¼National Cancer Institute Common
Toxicity Criteria for Adverse Events.
aPeripheral neuropathy was reported in an additional 5 (13%) patients at 75mgm 2 and 3
(16%) at 100mgm 2.
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of unrelated and transient grade 3 hypertension was observed. BP
abnormalities were reported in eight patients, most of which were
transient. A retrospective expert cardiologic evaluation confirmed
these results.
Anti-tumour activity. All patients were evaluated for response
according to RECIST 1.0 (Table 5). Ten patients (17%) had partial
responses (PRs), seven with breast cancer, and one each with
prostate, ovarian or oesophageal carcinoma. Seven of the
responders were treated at 30/100mgm 2 and all had a previous
best response of SD or disease progression. Seven of the 33 patients
who had previously received taxanes had PR with the ombrabulin/
docetaxel doublet (two had a previous best response of PR and one
had SD under docetaxel, and four were treated in the adjuvant
setting). Eight PRs lasted for more than 3 months (range 2.7–8.5)
with a median duration of 5.3 months. Stable disease was reported
in 27 patients (47%) at a range of dose levels, with a median
duration of 4.6 months. The rate of disease control (PRþ SD) was
81% in breast cancer patients (17 out of 21), 64% in oesophageal
cancer patients (9 out of 14) and 100% in the three prostate cancer
patients.
Pharmacokinetics. The pharmacokinetics of ombrabulin and its
active metabolite RPR258063 were evaluated in 57 patients and
pharmacokinetics of docetaxel were evaluated in 56 patients.
A summary of results is provided in Table 6 and concentration
time profiles of ombrabulin, its active metabolite RPR258063 and
docetaxel are shown in Figure 1. Exposure to ombrabulin and
RPR258063 was dose proportional with mean AUC ranging from
290 ng*hml 1 to 856 ng*hml 1 and from 394 ng*hml 1 to
1830 ng*hml 1, respectively. For ombrabulin, elimination was
biphasic with rapid conversion to RPR258063 (mean half-life
12min) and high clearance of 67 l h 1m 2, whereas steady state
volume of distribution was low at 30 lm 2. For RPR258063, a
biphasic or triphasic elimination profile was observed with a
terminal half-life of 8 h. For docetaxel, mean clearance was
25.2±8.1 and 23.2±5.0 l h 1m 2 after 75 and 100mgm 2,
respectively, corresponding to AUCs of 5.12±12.4 mg*hml 1 and
4.59±1.38 mg*hml 1. One patient receiving 75mgm 2 docetaxel
had a very high AUC (79.4 mg*hml 1). When this value was
excluded, mean AUC was 3.11±0.84 mg*hml 1.
Table 5. Tumour response according to RECIST
75mgm 2
docetaxel
(N¼39)
100mgm 2
docetaxel
(N¼19)
All
(N¼58)
Best overall response
PR 3 (7.7%) 7 (36.8%) 10 (17.2%)
Stable disease 18 (46.2%) 9 (47.4%) 27 (46.6%)
Disease progression 17 (43.6%) 3 (15.8%) 20 (34.5%)
Not evaluable 1 (2.6%) 0 1 (1.7%)
Abbreviations: PR¼partial response; RECIST¼Response Evaluation Criteria in Solid
Tumours.
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Figure 1. Concentration-time profiles of ombrabulin, its active metabolite RPR258063 and docetaxel. Plasma concentrations in cycle 1 are shown
for (A) ombrabulin and (B) RPR258063 by dose level according to median concentrations (N¼57), and for docetaxel (C) 75mgm2 (N¼38) and
(D) 100mgm2 (N¼18) presenting individual results against predicted values for a patient with a body surface area of 1.76m2 and 1.89m2,
respectively.
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DISCUSSION
The current study demonstrates the feasibility of integrating
ombrabulin into two standard docetaxel regimens of 75 and
100mgm 2, which are approved for use in a variety of clinical
settings in different tumour types. Three DLTs were reported
with each docetaxel dose. Neutropaenic complications were
dose-limiting at lower ombrabulin doses (25 and 30mgm 2)
with both docetaxel doses, while headache, fatigue, and thrombosis
were dose-limiting at 35 and 42mgm 2 ombrabulin with both
docetaxel doses. The recommended combination doses for further
clinical studies were therefore set at 35mgm 2 ombrabulin/
75mgm 2 docetaxel and 30mgm 2 ombrabulin/100mgm 2
docetaxel.
The DLTs reported are consistent with the single-agent profiles.
Neutropaenic complications are associated with docetaxel, but
were not reported with single-agent ombrabulin (Sessa et al, 2013).
Headache and fatigue were frequent with ombrabulin, and grade
3 thrombosis occurred at the highest ombrabulin single-agent dose
evaluated (50mgm 2), although none of these toxicities were
dose-limiting with ombrabulin monotherapy. The addition of
ombrabulin to docetaxel at doses commonly used in standard
therapeutic regimens did not compromise the safety of either
agent, and there was no indication of prolonged or cumulative
toxicities. As expected, prominent toxicities associated with
docetaxel were dose-dependent grade 3-4 neutropaenia and
leukopaenia. Common grade 1–2 non-haematological toxicities
such as asthaenia, nausea, vomiting, diarrhoea, and neuropathy
are coherent with the toxicity profiles of both docetaxel
(75 and 100mgm 2) and ombrabulin (Sessa et al, 2013), as was
the higher frequency of diarrhoea, nail disorders, oedema, and
neuropathy with 100mgm 2 docetaxel compared with
75mgm 2 (Extra et al, 1993; Harvey et al, 2006). Other
ombrabulin-related toxicities such as headache and abdominal
pain were reported but were only mild (grade 1–2). Notably,
tumour pain which is considered to be VDA dose-dependent
was rarely reported at the two ombrabulin combination RP2Ds
(30 and 35mgm 2). Overlapping toxicities for the two agents,
notably asthaenia, digestive toxicities, abdominal pain, and
neuropathy, rarely required dose reductions or delays.
An expert cardiovascular review concluded that with the absence
of ischemic episodes, cardiac decompensation, ECG, and cardiac
biomarker abnormalities, and no cases of related hypertension
notably in the ten patients with a history of hypertension, the
addition of ombrabulin to docetaxel at the proposed RP2Ds does not
impose cardiovascular restrictions. This supports previous reports
that cardiovascular toxicity does not present a limitation to
ombrabulin use (Soria et al, 2008; Sessa et al, 2013). Nonetheless,
and given the as yet limited clinical experience with ombrabulin,
appropriate screening and close cardiovascular surveillance during
treatment remain a recommended aspect of ombrabulin use.
It has been suggested that the strategy of combining a
chemotherapeutic agent with a VDA may prevent development
of a rim of viable tumour cells surrounding the necrotic core which
is characteristic of advanced solid tumours (Tozer et al, 2005). This
not only targets the proliferating border of tumours, but also offers
a potential means of overcoming drug resistance which can impose
limitations on the use of cytotoxic agents. Although intriguing
preclinical evidence has urged exploration of this sequence in a
clinical setting, the exact molecular explanation for how ombra-
bulin and docetaxel interact has not been fully elucidated. In a
recent review (McKeage and Baguley, 2010), it was suggested that
VDAs are able to access poorly perfused regions which are
inaccessible to chemotherapy molecules (Siim et al, 2003). Another
possibility is that VDAs result in decreased tumoural clearance of
chemotherapy agents and increased tumoural susceptibility to
chemotherapeutic agents via micro-environmental changes (Pruijn
et al, 1997).
Pharmacokinetic analyses of ombrabulin over the 24 h following
its administration showed dose proportionality and rapid conver-
sion to its metabolite RPR258063. As expected with this analysis
performed prior to docetaxel administration, the outcome was
similar to that reported in the monotherapy study (Sessa et al,
2013), although volume of distribution and clearance were higher
than with monotherapy. Docetaxel parameters following ombra-
bulin administration were also consistent with published single-
agent data (Bruno et al, 1998; Harvey et al, 2006). Systemic
exposure of docetaxel thus does not appear to be altered by
preceding administration of ombrabulin 24 h earlier, confirming
the absence of relevant drug interaction when administered
according to this schedule.
Responses and durable SD were seen across all dose levels.
Several PRs were reported in breast cancer patients, which is
coherent with reported response rates ranging from 23% to 48%
with single-agent docetaxel in metastatic breast cancer patients
(Bonneterre et al, 1999; Chan et al, 1999; Nabholtz et al, 1999;
Sjostrom et al, 1999; Bonneterre et al, 2002; Jones et al, 2005).
Activity in oesophageal cancer patients was encouraging and
although only three prostate cancer patients were included, all had
clinical benefit suggesting further investigation in these indications
may be worthwhile.
Evaluation of biomarkers indicative of sensitivity to tubulin-
interacting agents, tumour vascularisation or angiogenesis and
endothelial cells is an important step in the clinical development of
ombrabulin in order to establish a predictive signature, with the
ratio of mature to immature vessel markers potentially correlating
with response outcome. An exploratory analysis performed as part
of this study, unfortunately, did not show clear correlations
between biomarker expression in archived tissue and outcome. It
has to be emphasised that our analysis was hampered by the small
sample size and very few on-study evaluations and further
investigation of these parameters therefore is needed.
This study has determined the ombrabulin recommended doses
for further clinical development in combination with two docetaxel
doses that are frequently used in standard 3-weekly schedules.
In an extension of this regimen, the addition of ombrabulin to
platinum/taxane doublets has meanwhile been evaluated in a phase
II study in non-small cell lung cancer patients (von Pawel et al,
2012). Further studies to assess the added value of ombrabulin to
other cytotoxic regimens will be undertaken.
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